首页 > 市场调查报告书 > 医疗设备

生技设备

次世代定序在临床肿瘤学中的市场规模、份额和成长分析（按技术、工作流程、应用、最终用途和地区划分）—2026-2033年产业预测

市场调查报告书

商品编码

1896837

次世代定序在临床肿瘤学中的市场规模、份额和成长分析（按技术、工作流程、应用、最终用途和地区划分）—2026-2033年产业预测

Clinical Oncology Next Generation Sequencing Market Size, Share, and Growth Analysis, By Technology, By Workflow, By Application, By End-use, By Region - Industry Forecast 2026-2033

出版日期: 2025年12月17日 | 出版商:

SkyQuest | 英文 242 Pages | 商品交期: 3-5个工作天内

价格

简介目录

全球次世代定序市场规模预计在 2024 年达到 4.4042 亿美元，从 2025 年的 5.1045 亿美元增长到 2033 年的 16.6195 亿美元，在预测期（2026-2033 年）内复合年增长率为 15.9%。

次世代定序(NGS) 技术透过实现全基因组的快速、扩充性定序，彻底革新了临床肿瘤学，显着改善了个人化癌症治疗策略。该技术有助于识别新型和罕见的癌症突变，检测家族内的遗传突变，并为优化标靶治疗提供重要的遗传资讯。 NGS 工作流程的关键环节是 DNA 预处理，它为精确定序准备样本。此外，先进的平台能够分析原始 NGS 数据，使医学专家能够结合实验性和已通过核准的疗法来评估基因组突变。因此，NGS 数据处理系统对于确保针对不同基因型患者及其相应的药物反应提供更有效的治疗方案，以及实现个体化肿瘤治疗至关重要。

推动全球临床肿瘤学次世代定序市场发展的因素

全球临床肿瘤学次世代定序市场正经历显着成长，这主要得益于几个关键因素。对能够进行次世代定序(NGS) 的先进技术的需求不断增长，这与人们对个人化医疗和伴随诊断检测日益增长的兴趣相契合。此外，NGS 在液态生物检体的应用不断扩展，预计将为该行业带来可观的收入。这种创新方法能够对循环肿瘤 DNA 进行定序，从而实现非侵入性、即时的癌症分析和监测。此外，肿瘤学研究经费的增加也促进了全球临床肿瘤学 NGS 解决方案市场的扩张。

限制全球临床肿瘤学次世代定序市场发展的因素

由于这些先进诊断流程高成本，全球临床肿瘤学次世代定序市场面临严峻挑战。世界各地的患者都面临临床肿瘤定序的高昂费用，这给医疗系统带来了巨大的压力，迫使其证明这些支出的合理性。在许多地区，政治不稳定和经济困难引发了人们对公共医疗资金永续性的担忧。这种情况在低收入国家尤其严重，缺乏负担得起的癌症治疗对公众健康和预期寿命产生了负面影响。此外，治疗罕见癌症所需的耗材和专用设备的高昂价格也进一步阻碍了市场成长。

全球临床肿瘤学次世代定序市场趋势

全球临床肿瘤学次世代定序(NGS) 市场正经历着重大的模式转移，主要得益于 NGS 在液态生物检体应用中日益广泛的应用。这项创新技术能够对循环肿瘤 DNA定序，从而实现对癌症进展的非侵入性即时监测。凭藉其同时定序多个基因组的先进能力，NGS 技术正逐渐成为癌症诊断的基础。其速度快、灵敏度高、成本效益高等固有优势正推动 NGS 在临床领域的应用，许多检查室已将其纳入常规诊断流程。因此，这一趋势预计将推动市场成长，并重新定义癌症治疗策略。

北美洲
- 美国
- 加拿大
欧洲
- 德国
- 西班牙
- 法国
- 英国
- 义大利
- 其他欧洲地区
亚太地区
- 中国
- 印度
- 日本
- 韩国
- 亚太其他地区
拉丁美洲
- 巴西
- 其他拉丁美洲地区
中东和非洲
- 海湾合作委员会国家
- 南非
- 其他中东和非洲地区

竞争资讯

前五大公司对比
主要企业的市场定位（2025 年）
主要市场参与者所采取的策略
近期市场趋势
公司市占率分析（2025 年）
主要企业公司简介
- 公司详情
- 产品系列分析
- 依业务板块进行公司股票分析
- 2023-2025年营收年比比较

主要企业简介

Illumina, Inc.（US）
Thermo Fisher Scientific, Inc.（US）
F. Hoffmann-La Roche AG（Switzerland）
Qiagen NV（Netherlands）
Agilent Technologies, Inc.（US）
BGI Genomics Co., Ltd.（China）
PerkinElmer, Inc.（US）
Oxford Nanopore Technologies, Inc.（UK）
Pacific Biosciences of California, Inc.（US）
Eurofins Scientific SE（Luxembourg）
Myriad Genetics, Inc.（US）
Guardant Health, Inc.（US）
Natera, Inc.（US）
Biocartis Group NV（Belgium）

结论与建议

简介目录

Product Code: SQMIG35H2071

Global Clinical Oncology Next Generation Sequencing Market size was valued at USD 440.42 Million in 2024 and is poised to grow from USD 510.45 Million in 2025 to USD 1661.95 Million by 2033, growing at a CAGR of 15.9% during the forecast period (2026-2033).

Next-generation sequencing (NGS) has revolutionized clinical oncology by enabling rapid and scalable sequencing of entire genomes, markedly enhancing personalized cancer treatment strategies. This technology allows for the identification of novel and rare cancer mutations, facilitates the detection of hereditary mutations in family members, and provides essential genetic insights to optimize targeted therapies. A critical component of the NGS workflow is DNA pre-sequencing, which prepares samples for accurate sequencing. Furthermore, advanced platforms analyze raw NGS data, empowering healthcare professionals to assess genomic alterations in conjunction with experimental and approved therapies. Consequently, NGS data processing systems are increasingly pivotal for delivering tailored oncology care, ensuring more effective treatment options for diverse patient genotypes and their corresponding drug responses.

Top-down and bottom-up approaches were used to estimate and validate the size of the Global Clinical Oncology Next Generation Sequencing market and to estimate the size of various other dependent submarkets. The research methodology used to estimate the market size includes the following details: The key players in the market were identified through secondary research, and their market shares in the respective regions were determined through primary and secondary research. This entire procedure includes the study of the annual and financial reports of the top market players and extensive interviews for key insights from industry leaders such as CEOs, VPs, directors, and marketing executives. All percentage shares split, and breakdowns were determined using secondary sources and verified through Primary sources. All possible parameters that affect the markets covered in this research study have been accounted for, viewed in extensive detail, verified through primary research, and analyzed to get the final quantitative and qualitative data.

Global Clinical Oncology Next Generation Sequencing Market Segments Analysis

Global Clinical Oncology Next Generation Sequencing Market is segmented by Technology, Workflow, Application, End-use and region. Based on Technology, the market is segmented into Whole Genome Sequencing, Whole Exome Sequencing and Targeted Sequencing & Resequencing. Based on Workflow, the market is segmented into NGS Pre-Sequencing, NGS Sequencing and NGS Data Analysis. Based on Application, the market is segmented into Screening, Sporadic Cancer, Inherited Cancer, Companion Diagnostics and Other Diagnostics. Based on End-use, the market is segmented into Hospitals, Clinics and Laboratories. Based on region, the market is segmented into North America, Europe, Asia Pacific, Latin America and Middle East & Africa.

Driver of the Global Clinical Oncology Next Generation Sequencing Market

The Global Clinical Oncology Next Generation Sequencing market is experiencing significant growth driven by several key factors. The rising demand for advanced technologies capable of performing next-generation sequencing (NGS) aligns with the increasing interest in personalized medicine and diagnostic companion tests. Furthermore, enhancing the application of NGS for liquid biopsies is expected to generate substantial revenue within the industry. This innovative approach allows for the sequencing of circulating tumor DNA, enabling non-invasive real-time cancer profiling and monitoring. Additionally, an increase in funding for oncology research contributes to the expansion of the global market for clinical oncology NGS solutions.

Restraints in the Global Clinical Oncology Next Generation Sequencing Market

The Global Clinical Oncology Next Generation Sequencing market faces significant challenges due to the high costs associated with these advanced diagnostic processes. Patients worldwide grapple with the prohibitive expenses of clinical oncology sequencing, which places immense pressure on healthcare systems to justify these costs. In many regions, political instability and economic difficulties are raising concerns about the sustainability of public healthcare funding. This situation is particularly dire in countries with low income levels, where the lack of affordable cancer treatments adversely affects overall public health and life expectancy. Furthermore, the steep prices of essential consumables and specialized equipment for rare cancer treatments further hinder market growth.

Market Trends of the Global Clinical Oncology Next Generation Sequencing Market

The Global Clinical Oncology Next Generation Sequencing (NGS) market is witnessing a significant paradigm shift, driven by the increasing implementation of NGS in liquid biopsy applications. This innovation enables the sequencing of circulating tumor DNA, facilitating non-invasive and real-time monitoring of cancer progression. With advanced capabilities that allow simultaneous sequencing of multiple genomes, NGS technology is becoming a cornerstone in cancer diagnostics. Its inherent advantages-speed, sensitivity, and cost-effectiveness-are propelling its adoption in clinical settings, and many laboratories are transitioning to routine diagnostic applications. Consequently, this trend is poised to enhance market growth and redefine cancer treatment strategies.

Introduction

Objectives of the Study
Scope of the Report
Definitions

Research Methodology

Information Procurement
Secondary & Primary Data Methods
Market Size Estimation
Market Assumptions & Limitations

Executive Summary

Global Market Outlook
Supply & Demand Trend Analysis
Segmental Opportunity Analysis

Market Dynamics & Outlook

Market Overview
Market Size
Market Dynamics
- Drivers & Opportunities
- Restraints & Challenges
Porters Analysis
- Competitive rivalry
- Threat of substitute
- Bargaining power of buyers
- Threat of new entrants
- Bargaining power of suppliers

Key Market Insights

Key Success Factors
Degree of Competition
Top Investment Pockets
Market Ecosystem
Market Attractiveness Index, 2025
PESTEL Analysis
Macro-Economic Indicators
Value Chain Analysis
Pricing Analysis
Case Study Analysis

Global Clinical Oncology Next Generation Sequencing Market Size by Technology & CAGR (2026-2033)

Market Overview
Whole Genome Sequencing
Whole Exome Sequencing
Targeted Sequencing & Resequencing

Global Clinical Oncology Next Generation Sequencing Market Size by Workflow & CAGR (2026-2033)

Market Overview
NGS Pre-Sequencing
NGS Sequencing
NGS Data Analysis

Global Clinical Oncology Next Generation Sequencing Market Size by Application & CAGR (2026-2033)

Market Overview
Screening
Sporadic Cancer
Inherited Cancer
Companion Diagnostics
Other Diagnostics

Global Clinical Oncology Next Generation Sequencing Market Size by End-use & CAGR (2026-2033)

Market Overview
Hospitals
Clinics
Laboratories

Global Clinical Oncology Next Generation Sequencing Market Size & CAGR (2026-2033)

North America (Technology, Workflow, Application, End-use)
- US
- Canada
Europe (Technology, Workflow, Application, End-use)
- Germany
- Spain
- France
- UK
- Italy
- Rest of Europe
Asia Pacific (Technology, Workflow, Application, End-use)
- China
- India
- Japan
- South Korea
- Rest of Asia-Pacific
Latin America (Technology, Workflow, Application, End-use)
- Brazil
- Rest of Latin America
Middle East & Africa (Technology, Workflow, Application, End-use)
- GCC Countries
- South Africa
- Rest of Middle East & Africa

Competitive Intelligence

Top 5 Player Comparison
Market Positioning of Key Players, 2025
Strategies Adopted by Key Market Players
Recent Developments in the Market
Company Market Share Analysis, 2025
Company Profiles of All Key Players
- Company Details
- Product Portfolio Analysis
- Company's Segmental Share Analysis
- Revenue Y-O-Y Comparison (2023-2025)

Key Company Profiles

Illumina, Inc. (US)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Thermo Fisher Scientific, Inc. (US)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
F. Hoffmann-La Roche AG (Switzerland)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Qiagen N.V. (Netherlands)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Agilent Technologies, Inc. (US)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
BGI Genomics Co., Ltd. (China)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
PerkinElmer, Inc. (US)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Oxford Nanopore Technologies, Inc. (UK)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Pacific Biosciences of California, Inc. (US)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Eurofins Scientific SE (Luxembourg)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Myriad Genetics, Inc. (US)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Guardant Health, Inc. (US)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Natera, Inc. (US)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Biocartis Group NV (Belgium)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments